---
title: "CRIS Connect: Fostering Collaborations to Advance Clinical Research and
  Therapeutic Development"
permalink: /cris-connect-fostering-collaborations-to-advance-clinical-research-and-therapeutic-development/
date: 2026-02-11
layout: post
description: ""
image: ""
variant: tiptap
---
<p></p>
<p></p>
<div class="isomer-image-wrapper">
<img style="width: 100%" height="auto" width="100%" alt="" src="/images/CRIS_Connect_Feb_2026.jpg">
</div>
<p></p>
<h4><strong>Registration</strong></h4>
<p><strong>Please register via</strong>  <strong><a href="https://for.sg/crisconnect" rel="noopener noreferrer nofollow" target="_blank"><u>https://for.sg/crisconnect</u></a></strong>
</p>
<p>Registration closes Thu, 26 Feb 2026.</p>
<hr>
<h4><strong>About the Speakers</strong></h4>
<p><strong>A/Prof Melvin Chua</strong>
<br><em>Head and Senior Consultant</em>
<br><em>Department of Head and Neck and Thoracic Cancers, National Cancer Centre Singapore (NCCS)</em>
</p>
<p>A/Prof Melvin Chua is a Clinician-Scientist at the National Cancer Centre
Singapore (NCCS) and the Duke-NUS Medical School. He is currently an Associate
Professor (On Tenure) of Duke-NUS Medical School, Singapore; Visiting Professor
of the Zhongnan Hospital of Wuhan University, China. He is also a Principal
Investigator of the Precision Radiotherapeutics and Oncology Programme
(PROP).</p>
<p>Additionally, he is the Department Head and Senior Consultant for the
Department of Head and Neck and Thoracic Radiation Oncology, and Director
of the Data and Computational Science Hub at the NCCS. A/Prof Chua has
published over 230 peer-reviewed papers, with a H-index of 48 (&gt;13,000
citations); He is the Lead Author of the Nasopharynx Cancer Chapter of
the 12th edition of the Cancer: Principles &amp; Practice of Oncology –
the most widely-used oncology textbook worldwide, as well as other highly
cited articles in the New England Journal of Medicine, Lancet, Nature,
Cell, Journal of Clinical Oncology and JAMA Oncology.</p>
<p>Consequently, he is listed as the World’s Top 2% Most Cited Scientists
in consecutive years from 2023 to 2025. For his work, he has received numerous
honours, including the SingHealth Excellence Distinguished Researcher Award,
Conquer Cancer Foundation ASCO Merit Awards, NMRC Clinician-Scientist Award
(Investigator), Fellow of the Royal College of Radiologists, Fellow of
the Academy of Medicine Singapore (FAMS), and Fellow of the American Society
of Clinical Oncology (FASCO; first Singaporean National to be inducted
for class of 2025).</p>
<p><strong>Dr Robin Chan</strong>
<br><em>Scientific Director<br>Singapore Translational Cancer Consortium (STCC), Consortium for Clinical Research and Innovation, Singapore (CRIS)</em>
</p>
<p>As the Scentific Director of Singapore Translational Cancer Consortium
(STCC), Dr Robin Chan oversees the development and coordination of collaborative,
investigator-led cancer research across Singapore’s public healthcare and
academic institutions. His work involves strengthening translational research
platforms, supporting investigator-initiated studies, and fostering strategic
partnerships that bridge healthcare institutions, academia, and industry.</p>
<p>Dr Chan received his PhD in Biochemistry and completed his academic training
at the National University of Singapore and Columbia University Medical
Center. He has over 15 years of experience spanning academic research and
the biotechnology industry, with expertise in multi-omics analysis and
translational biology in neurodegeneration, infectious diseases and oncology.</p>
<p>Prior to joining STCC, he held senior scientific and strategic roles in
biotechnology, where he led the development of multi-omics research platforms
and cross-institutional academic–industry collaborations.&nbsp;</p>